Olaratumab

奥拉单抗

Report date: 2024/03/26 14:47:40

Base Information

Drug NameOlaratumab
Drug Alias NameAnti-PDGFRα mAb 3G3奥拉妥单抗奥拉单抗LartruvoIMC-3G3 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionPlatelet-derived growth factor receptor alpha inhibitors
TargetsPlatelet-derived growth factor receptor alpha
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms +[15] 
Global Approved IndicationsSarcoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/10/19
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineEli Lilly And CompanyTelix Pharmaceuticals Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsHemangiosarcomaSarcomaLeiomyosarcoma +[8] 
Inactive IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms +[7] 

Other Information

ATC CodeL01XC27
Related LinksWikipediaKEGG